GenomeWeb is very widely read. There is no longer any reason for clinicians to say that they hadn't heard or the test, are unsure about it or need more evidence.
The key strength of the tests (as reported) is the high negative predictive value. Being able to tell many patients that you are 96% or 98 % sure that they don't have bladder cancer (and maybe to take a second test in a few months time to be absolutely sure) MEANS EVERYTHING.
The stats do the talking!
cheers
GenomeWeb is very widely read. There is no longer any reason for...
-
- There are more pages in this discussion • 267 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.002(28.6%) |
Mkt cap ! $4.152M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 1.0¢ | 0.8¢ | $7.869K | 812.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2409444 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 227219 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |